|1.||Jankowski, Michael P: 2 articles (01/2014 - 01/2010)|
|2.||Glick, Ira D: 2 articles (10/2011 - 08/2006)|
|3.||Lustig, Daniel Ben: 1 article (12/2015)|
|4.||Rodriguez, Rosendo: 1 article (12/2015)|
|5.||Wells, Philip S: 1 article (12/2015)|
|6.||Shi, Luwen: 1 article (11/2015)|
|7.||Wu, Min: 1 article (11/2015)|
|8.||Li, Shao: 1 article (11/2015)|
|9.||Lu, Peng: 1 article (11/2015)|
|10.||Yano, Kyoko: 1 article (09/2015)|
07/01/2014 - "Such programs can be guaranteed by the Centers for Pain Management (CPMs), in which multidisciplinary teams are able to provide advanced and specialized activities for the assessment, diagnosis and treatment of chronic benign pain. "
01/01/1996 - "5. The induction of adrenergic excitability in CPMs by sympathectomy is suggested to be a counterpart to postsympathectomy neuralgia in human beings and a possible part of the mechanism leading to sympathetically related pain states."
01/01/1999 - "A significant reduction in subjective complaints as measured by a combined pain-mobility score (CPMS) was found in both fluoride groups in comparison with the calcium monotherapy group. "
12/01/2001 - "We report the relationship between priming of CD4 and CD8 T cells for interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) and disease evolution in MS patients, clinically subdivided into relapsing-remitting MS (RRMS) in remission, RRMS in relapse, or chronic progressive MS (CPMS). "
|3.||Chronic Progressive Multiple Sclerosis
09/25/1992 - "Participation offered to all clinically definite chronic progressive multiple sclerosis (CPMS) patients attending clinic ages 21 to 60, disease duration > 1 year, Expanded Disability Status Scale (EDSS) score 3.0 to 6.5 (ambulatory with moderate disability). "
04/01/1989 - "We have previously shown that CsA prevented continued activation of T-cells in chronic progressive multiple sclerosis (CPMS) patients. "
01/01/1989 - "Computer-assisted quantitation of magnetic resonance images revealed a higher mean lesion load in chronic progressive multiple sclerosis (CPMS); however, in approximately 20% of benign MS patients the lesion load was higher than that in the CPMS patients. "
01/01/1995 - "To examine the hypothesis that addition of therapeutic plasma exchange (TPEX) to an immunosuppressive drug regimen increases that regimen's efficacy to halt the progression of chronic progressive multiple sclerosis (CPMS). "
11/01/2012 - "In this study, chronic progressive multiple sclerosis (CPMS) patients receiving the experimental drug MBP8298, on a compassionate care trial, were examined before and after high dose peptide treatment for their circulating regulatory T-cell numbers and their responses to the common mitogens, phytohemagglutinin and poke-weed mitogen. "
12/01/2015 - "Newly diagnosed cancer patients can be readily stratified into intermediate-high and low risk of VTE using our novel CPMS system. "
12/01/2015 - "To create and assess the feasibility of an innovative computerized Care Process Management System (CPMS) that would automatically access electronic medical records to calculate in real-time the risk of VTE in patients with active cancer using an established VTE risk scoring system. "
11/10/2015 - "Moreover, 24.8% of the cancer patients used both CPMs and WMs, and CPM-WM combined use networks were constructed for four major cancers. "
11/10/2015 - "The cancer profile of commonly used CPMs and WMs for the top 17 cancers (>500 sampled patients) were provided, indicating anticancer CPMs had a broad spectrum of cancers and lacked selectivity in cancer treatment (CPM mean CV = 49%; WM mean CV = 152%). "
11/10/2015 - "We found that 42.4% of 51,382 cancer patients used 33 anticancer CPMs, and 51.7% used 71 anticancer Western medicines (WMs). "
01/01/1995 - "We analyzed the CPMS data to test whether a white-cell count spike at least 15 percent above the previous measurement predicted agranulocytosis within 75 days, with a 21-day lag to allow white-cell counts to decline to levels indicative of agranulocytosis. "
07/15/1993 - "We evaluated the CPMS data for February 1990 through April 1991 by survival analysis to determine the incidence of agranulocytosis and the effects of potential risk factors such as age and sex. "
01/01/1995 - "The incidence of agranulocytosis after 1 year was .80 percent in 11,555 patients registered in the Clozaril Patient Management System (CPMS) who received clozapine from February 1990 to April 1991. "
01/01/1989 - "The Clozaril Patient Management System (CPMS) has been developed to provide a 100% fail-safe system for monitoring white blood cell counts (WBCs) in patients being treated with clozapine (Clozaril/Leponex) in the United States and to provide comprehensive data collection on the incidence and development of agranulocytosis. "
05/18/1998 - "In the 4061 patients prospectively monitored by the CPMS, the incidence of agranulocytosis, neutropenia and leukopenia combined was 2.6% (n = 104); the incidence of agranulocytosis was 0.9% (n = 37). "
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Interferon-gamma (Interferon, gamma)
|7.||Anti-Anxiety Agents (Anxiolytics)
|9.||Hypnotics and Sedatives (Sedatives)
|10.||Antidepressive Agents (Antidepressants)
|2.||Drug Therapy (Chemotherapy)